Perhaps targeting FOXO1, a transcriptional driver of stemness in glioblastoma, will prove more effective in the clinic than other therapies as the cancer stem cells are strongly associated with poor prognosis [76,77,78]. Here, FOXO1 is linked to glioblastoma.